

BD Releases 2016 Sustainability Report

FRANKLIN LAKES, N.J., June 6, 2017 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued its [2016 Sustainability Report](#).

BD's sustainability strategy is driven by its purpose – *advancing the world of health*. The report describes BD's progress against its 2020 Sustainability Goals in four key strategic areas:

- Innovation – health care safety, outcomes and cost
- Access – health care in resource-limited populations
- Efficiency – environmentally sound products and resilient operations
- Empowerment – positive workforce and community impacts.

Key highlights include:

- **Innovation** – BD has continued to innovate in key areas such as medication management, lab automation and disease management, launching a number of significant new products and solutions to tackle global health issues such as patient and health care worker safety, medication management, antimicrobial resistance, influenza, diabetes and cancer. In 2016, BD was named a Thompson Reuters Top 100 Global Innovator and added to the CNBC IQ100 Index.
- **Access** – BD works with various partners and countries around the world to drive access to life-saving technologies, strengthen health care systems and address priority health needs. In its eighth year, the BD-PEPFAR Labs for Life partnership is strengthening laboratories across India, Uganda, Mozambique, Ethiopia and Kenya. BD also entered into two, new collaborations with the CDC to address the transmission of disease in medical settings.
- **Efficiency** – BD demonstrated significant progress towards its 2020 Sustainability Goals in the categories of emissions, energy, waste and water. Notably, 43 percent of the company's total energy is generated from renewable sources – significant progress to reaching its 2020 Goal of 50 percent, and the company has reduced water consumption globally by 34 percent. The company has also continued to focus on eliminating materials of concern and reducing the lifecycle impact of many of its products.
- **Empowerment** – As BD has become increasingly diverse, BD has set goals to improve inclusion and diversity at all levels of the organization. BD has continued to support non-profit and educational organizations around the world through the donation of more than \$18 million in cash, product and expertise. Organizations benefitting include the BD Helping Build Healthy Communities™ initiative, implemented together with Direct Relief and the National Association of Community Health Centers; Together For Girls; and the BD U.S. Fund for UNICEF Maternal and Neonatal Tetanus Elimination Campaign.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com

For more information on BD, please visit bd.com.

Troy Kirkpatrick

858 617 2361

[Email Troy](#)
